PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33280445-2	2021	One such inhibitor, abemaciclib, a reversible ATP-competitive CDK4/6 inhibitor developed by Eli Lilly and Company, was approved by the FDA for ER-positive, HER2-negative metastatic breast cancer.	abemaciclib	20-31	cyclin dependent kinase 4	Homo sapiens	62-68
33280445-2	2021	One such inhibitor, abemaciclib, a reversible ATP-competitive CDK4/6 inhibitor developed by Eli Lilly and Company, was approved by the FDA for ER-positive, HER2-negative metastatic breast cancer.	abemaciclib	20-31	epiregulin	Homo sapiens	143-145
33280445-2	2021	One such inhibitor, abemaciclib, a reversible ATP-competitive CDK4/6 inhibitor developed by Eli Lilly and Company, was approved by the FDA for ER-positive, HER2-negative metastatic breast cancer.	abemaciclib	20-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
33867426-2	2022	The objective of this study was to describe treatment patterns, clinical outcomes, and safety profiles among patients with HR+/HER2- MBC treated with palbociclib, abemaciclib, or everolimus in a clinical practice setting.	abemaciclib	163-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	cyclin dependent kinase 4	Homo sapiens	70-103
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	279-295
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	nuclear receptor subfamily 4 group A member 1	Homo sapiens	297-299
33968263-2	2021	Early results of the MonarchE trial investigating the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to standard adjuvant endocrine therapy indicated a lower recurrence rate in the combination group in a high-risk population of patients with early stage hormone receptor (HR)-positive/HER2-negative BC.	abemaciclib	114-125	erb-b2 receptor tyrosine kinase 2	Homo sapiens	310-314
32710211-7	2021	RESULTS: Our in vitro study demonstrated that sequential treatment of O6-Benzylguanine with either LY2385219 or LY2157299-enhanced temozolomide enhanced sensitivity in MGMT+ 43RG cells.	abemaciclib	99-108	O-6-methylguanine-DNA methyltransferase	Homo sapiens	168-172
33686753-0	2021	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.	abemaciclib	0-11	erb-b2 receptor tyrosine kinase 2	Homo sapiens	84-88
32710211-9	2021	Furthermore, LY2835219 has additional anti-proliferative effects on cell cycling, including induction of an RB-associated G (1) arrest via suppression of cyclin D-CDK4/6-Rb pathway.	abemaciclib	13-22	cyclin dependent kinase 4	Homo sapiens	163-169
33116117-8	2020	Metformin significantly modulated the profiles of the SASP elicited by LY2835219 by inhibiting the mTOR and stat3 pathways.	abemaciclib	71-80	signal transducer and activator of transcription 3	Homo sapiens	108-113
32789591-1	2020	PURPOSE: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC).	abemaciclib	50-61	NLR family pyrin domain containing 12	Homo sapiens	12-21
32789591-1	2020	PURPOSE: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC).	abemaciclib	50-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	185-189
33116117-5	2020	In this study, the efficacy of a combination of the CDK4/6 inhibitor LY2835219 and metformin in HNSCC was investigated in in vitro assays, an HSC6 xenograft model, and a patient-derived xenograft model.	abemaciclib	69-78	cyclin dependent kinase 4	Homo sapiens	52-58
32781837-0	2020	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.	abemaciclib	0-11	cyclin dependent kinase 6	Homo sapiens	24-28
33330839-3	2020	We discovered six compounds (cepharanthine, abemaciclib, osimertinib, trimipramine, colforsin, and ingenol) to be broad spectrum inhibitors for spike-mediated entry.	abemaciclib	44-55	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	144-149
33116117-8	2020	Metformin significantly modulated the profiles of the SASP elicited by LY2835219 by inhibiting the mTOR and stat3 pathways.	abemaciclib	71-80	mechanistic target of rapamycin kinase	Homo sapiens	99-103
32899250-6	2020	CDK2-mediated Rb phosphorylation and AKT phosphorylation appeared to be potential resistance mechanisms to abemaciclib monotherapy.	abemaciclib	107-118	cyclin dependent kinase 2	Homo sapiens	0-4
32899250-6	2020	CDK2-mediated Rb phosphorylation and AKT phosphorylation appeared to be potential resistance mechanisms to abemaciclib monotherapy.	abemaciclib	107-118	AKT serine/threonine kinase 1	Homo sapiens	37-40
31530780-11	2019	In clinical studies, abemaciclib has demonstrated efficacy and generally tolerable safety profile in HR-positive, HER2-negative breast cancer patients.	abemaciclib	21-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-118
32536013-12	2020	Combined with clinical efficacy, results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC.	abemaciclib	64-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
32536013-16	2020	Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC.	abemaciclib	53-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	110-114
32582803-0	2020	Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.	abemaciclib	0-11	cyclin dependent kinase 4	Homo sapiens	13-19
32835580-10	2020	Another CDK4/6 inhibitor, abemaciclib, also showed a synergistic effect.	abemaciclib	26-37	cyclin dependent kinase 4	Homo sapiens	8-14
31464525-0	2019	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.	abemaciclib	0-11	cyclin dependent kinase 4	Homo sapiens	22-47
31464525-0	2019	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.	abemaciclib	0-11	estrogen receptor 1	Homo sapiens	82-84
30014236-3	2018	CASE: We present a case of a 74-year-old woman who developed this rare and serious local side-effect in connective tissue following neoadjuvant CDK 4/6 inhibitor abemaciclib (Verzenio ) and aromatase inhibitor anastrozole (Arimidex ) therapy and subsequent radiation therapy of the breast.	abemaciclib	175-183	cyclin dependent kinase 4	Homo sapiens	144-151
31875784-0	2019	Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.	abemaciclib	59-70	cyclin dependent kinase 6	Homo sapiens	105-110
29429832-3	2018	Herein we report a novel series of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine anologues as potent CDK 4/6 inhibitors based on LY2835219 (Abemaciclib).	abemaciclib	198-207	cyclin dependent kinase 4	Homo sapiens	170-177
30165341-4	2018	The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor.	abemaciclib	206-215	cyclin dependent kinase 4	Homo sapiens	237-243
29716919-0	2018	Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo.	abemaciclib	0-11	cyclin dependent kinase 4	Homo sapiens	25-31
29074254-1	2017	The discovery of a class of diheteroaromatic amines based on LY2835219 as cyclin-dependent kinase (CDK1/4/6) inhibitors was described.	abemaciclib	61-70	cyclin dependent kinase 1	Homo sapiens	99-107
29125595-0	2017	Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.	abemaciclib	0-11	cyclin dependent kinase 4	Homo sapiens	32-39
29125595-0	2017	Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.	abemaciclib	13-21	cyclin dependent kinase 4	Homo sapiens	32-39
26896604-3	2016	The highly selective oral CDK 4/6 inhibitors palbociclib (PD0332991), ribociclib (LEE011), and abemaciclib (LY2835219) are able to inhibit the proliferation of Rb-positive tumor cells and have demonstrated dose-dependent growth inhibition in ER+ breast cancer models.	abemaciclib	108-117	cyclin dependent kinase 4	Homo sapiens	26-33
27748766-5	2017	After prolonged exposure to the selective and potent CDK4/6 inhibitor LY2835219, clones emerged and several were found to harbor amplification of the CDK6 kinase.	abemaciclib	70-79	cyclin dependent kinase 4	Homo sapiens	53-59
27748766-5	2017	After prolonged exposure to the selective and potent CDK4/6 inhibitor LY2835219, clones emerged and several were found to harbor amplification of the CDK6 kinase.	abemaciclib	70-79	cyclin dependent kinase 6	Homo sapiens	150-154
27816545-0	2017	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.	abemaciclib	23-32	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
27816545-0	2017	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.	abemaciclib	23-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	89-94
27816545-3	2017	Abemaciclib (LY2835219) is an orally bioavailable CDK4/6 inhibitor under phase III clinical trials.	abemaciclib	13-22	cyclin dependent kinase 4	Homo sapiens	50-56
27816545-4	2017	Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.	abemaciclib	20-29	ATP binding cassette subfamily B member 1	Homo sapiens	92-97
27816545-4	2017	Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.	abemaciclib	20-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	101-106
27816545-5	2017	Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.	abemaciclib	13-22	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
27816545-5	2017	Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.	abemaciclib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	150-155
27312735-0	2016	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.	abemaciclib	17-28	cyclin dependent kinase 4	Homo sapiens	46-57
27493615-3	2016	Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development.	abemaciclib	53-62	cyclin dependent kinase 4	Homo sapiens	21-27
27816545-6	2017	Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.	abemaciclib	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	64-69
27816545-6	2017	Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.	abemaciclib	17-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	74-79
27816545-8	2017	In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.	abemaciclib	55-64	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
27816545-8	2017	In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.	abemaciclib	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	87-92
26995305-12	2016	Abemaciclib (LY2835219), ribociclib (Lee011), and palbociclib (Ibrance( ) or PD0332991) target CDK4/6 with IC50 values in the low nanomolar range.	abemaciclib	13-22	cyclin dependent kinase 4	Homo sapiens	95-101
26909611-0	2016	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.	abemaciclib	21-30	cyclin dependent kinase 4	Homo sapiens	4-10
26909611-0	2016	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.	abemaciclib	21-30	mechanistic target of rapamycin kinase	Homo sapiens	71-75
26909611-2	2016	Here, we report the antiproliferative activity of LY2835219, a selective CDK4/6 inhibitor through inhibition of CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induction of cell cycle arrest in HNSCC cells.	abemaciclib	50-59	cyclin dependent kinase 4	Homo sapiens	73-79
26909611-2	2016	Here, we report the antiproliferative activity of LY2835219, a selective CDK4/6 inhibitor through inhibition of CDK4/6-dependent Ser780 phosphorylation in retinoblastoma (RB) and induction of cell cycle arrest in HNSCC cells.	abemaciclib	50-59	cyclin dependent kinase 4	Homo sapiens	112-118
26909611-5	2016	At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR.	abemaciclib	38-47	AKT serine/threonine kinase 1	Homo sapiens	72-75
26909611-5	2016	At the molecular level, we found that LY2835219 inhibited activation of AKT and ERK, but not mTOR.	abemaciclib	38-47	mitogen-activated protein kinase 1	Homo sapiens	80-83
26726315-4	2015	To date, three oral highly selective cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are in various stages of clinical development: PD0332991 (palbociclib), LEE011 (ribociclib) and LY2835219 (abemaciclib).	abemaciclib	182-191	cyclin dependent kinase 4	Homo sapiens	37-64
26726315-4	2015	To date, three oral highly selective cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are in various stages of clinical development: PD0332991 (palbociclib), LEE011 (ribociclib) and LY2835219 (abemaciclib).	abemaciclib	182-191	cyclin dependent kinase 4	Homo sapiens	77-84
25122067-0	2014	The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.	abemaciclib	21-30	cyclin dependent kinase 4	Homo sapiens	4-10
25122067-0	2014	The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.	abemaciclib	21-30	cyclin D1	Homo sapiens	101-110
25122067-4	2014	Here, we describe that cell lines with acquired resistance to vemurafenib show reactivation of MAPK signaling and upregulation of cyclin D1 and are sensitive to inhibition of LY2835219, a selective inhibitor of cyclin-dependent kinase (CDK) 4/6.	abemaciclib	175-184	cyclin dependent kinase 4	Homo sapiens	211-244
25122067-11	2014	Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.	abemaciclib	68-77	cyclin D1	Homo sapiens	38-47
25122067-11	2014	Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.	abemaciclib	68-77	cyclin dependent kinase 4	Homo sapiens	48-54
25122067-11	2014	Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.	abemaciclib	68-77	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	143-148
25122067-11	2014	Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.	abemaciclib	68-77	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	163-168
34407567-8	2022	Correspondingly, abemaciclib potentiated RRM1 reduction, resulting in sensitization to gemcitabine.	abemaciclib	17-28	ribonucleotide reductase catalytic subunit M1	Homo sapiens	41-45
24795392-7	2014	Three oral selective CDK4 inhibitors have entered clinical trials: palbociclib (PD0332991), LEE011, and LY2835219.	abemaciclib	104-113	cyclin dependent kinase 4	Homo sapiens	21-25
24919854-0	2014	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	abemaciclib	53-62	cyclin dependent kinase 4	Homo sapiens	36-42
24919854-4	2014	We present the identification and characterization of a potent CDK4/6 inhibitor, LY2835219.	abemaciclib	81-90	cyclin dependent kinase 4	Homo sapiens	63-69
24919854-5	2014	LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells.	abemaciclib	0-9	cyclin dependent kinase 4	Homo sapiens	19-23
24919854-5	2014	LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells.	abemaciclib	0-9	cyclin dependent kinase 6	Homo sapiens	28-32
24850847-0	2014	Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.	abemaciclib	87-96	cyclin-dependent kinase 4	Mus musculus	104-131
24850847-3	2014	Here, we present an integrated semi-mechanistic pharmacokinetic/pharmacodynamic model to characterize the quantitative pharmacology of LY2835219, a CDK4/6 inhibitor, in xenograft tumors.	abemaciclib	135-144	cyclin dependent kinase 4	Homo sapiens	148-154
24850847-4	2014	EXPERIMENTAL DESIGN: LY2835219 plasma concentrations were connected to CDK4/6 inhibition and cell-cycle arrest in colo-205 human colorectal xenografts by incorporating the biomarkers, phospho-(ser780)-Rb, topoisomerase II alpha, and phosphohistone H3, into a precursor-dependent transit compartment model.	abemaciclib	21-30	cyclin dependent kinase 6	Homo sapiens	71-77
24850847-7	2014	RESULTS: The model successfully described LY2835219-mediated CDK4/6 inhibition, cell-cycle arrest, and TGI in colo-205, and was validated in A375.	abemaciclib	42-51	cyclin dependent kinase 6	Homo sapiens	61-67
34593430-1	2021	BACKGROUND/AIM: LY2835219 (LY), a novel CDK4/6 inhibitor, prevents cell proliferation through G1 arrest.	abemaciclib	16-25	cyclin-dependent kinase 4	Mus musculus	40-46
34690920-3	2021	We herein report a case of a 60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC.	abemaciclib	133-144	cyclin dependent kinase 4	Homo sapiens	148-154
34593430-1	2021	BACKGROUND/AIM: LY2835219 (LY), a novel CDK4/6 inhibitor, prevents cell proliferation through G1 arrest.	abemaciclib	27-29	cyclin-dependent kinase 4	Mus musculus	40-46
34657059-0	2021	(A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole).	abemaciclib	105-116	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-55
34657059-4	2021	Asymptomatic multiple bone metastases on her ribs and sternum with bilateral lung metastasis and malignant effusion all disappeared while she was on a year- long administration of anastrozole and an optimal dose of abemaciclib(100 mg bid).	abemaciclib	215-226	BH3 interacting domain death agonist	Homo sapiens	234-237
34425869-13	2021	The analysis provides support for the use of abemaciclib plus fulvestrant (with ovarian suppression) as an effective treatment option for premenopausal patients with HR+, HER2- ABC who are ET-resistant.	abemaciclib	45-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-175
35121623-8	2022	Additional endpoints, including OS, were also improved following treatment with abemaciclib plus fulvestrant regardless of PIK3CA or ESR1 mutation status.	abemaciclib	80-91	estrogen receptor 1	Homo sapiens	133-137
35475118-8	2022	Therefore, Abemaciclib, Dasatinib and Spiperone are likely to be viable drug-candidate molecules that can block the interaction between the omicron spike protein and the host cellular receptor ACE2.	abemaciclib	11-22	angiotensin converting enzyme 2	Homo sapiens	193-197
35169388-2	2022	Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy.	abemaciclib	114-125	cyclin dependent kinase 4	Homo sapiens	97-103
35094535-6	2022	The CDK 4/6 inhibitor abemaciclib has been recently approved by the US FDA for patients at high risk of relapse.	abemaciclib	22-33	cyclin dependent kinase 4	Homo sapiens	4-11
35157829-17	2022	26 (100%) of 26 treated patients were p16ink4A deficient and received at least one dose of abemaciclib.	abemaciclib	91-102	cyclin dependent kinase inhibitor 2A	Homo sapiens	38-46
35135362-0	2022	Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.	abemaciclib	0-11	cyclin dependent kinase 4	Homo sapiens	36-42
35135362-0	2022	Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.	abemaciclib	0-11	erb-b2 receptor tyrosine kinase 2	Homo sapiens	87-91